BBIO BridgeBio Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BBIO

Price (delayed)

$65.71

Market cap

$12.85B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.56

Enterprise value

$14.66B

?
Relative Growth: Rel. Growth: 80
Relative Strength: Rel. Strength: 47
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 29

BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline ...

Highlights
The gross profit has soared by 197% YoY and by 22% from the previous quarter
BridgeBio Pharma's revenue has increased by 23% from the previous quarter
BridgeBio Pharma's quick ratio has plunged by 77% YoY and by 22% from the previous quarter
BBIO's equity is down by 41% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://bridgebio.com
Peers: OPK ORGO

Key stats

What are the main financial stats of BBIO

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-5.08%
1 week
-3.79%
1 month
-19.37%
1 year
27.59%
YTD
-14.09%
QTD
-11.77%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$713.07M
Gross profit
$673.41M
Operating income
-$497.8M
Net income
-$691.87M
Gross margin
94.4%
Net margin
-97%
The gross profit has soared by 197% YoY and by 22% from the previous quarter
BBIO's operating margin has soared by 75% YoY and by 23% QoQ
BBIO's net margin has surged by 71% year-on-year and by 22% since the previous quarter
BBIO's operating income is up by 24% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does BBIO's price correlate with its fundamentals

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
18.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.56
BBIO's EPS is up by 13% year-on-year and by 4.6% since the previous quarter
BBIO's equity is down by 41% year-on-year and by 10% since the previous quarter
The stock's price to sales (P/S) is 83% less than its 5-year quarterly average of 109.3 and 26% less than its last 4 quarters average of 25.7
BridgeBio Pharma's revenue has increased by 23% from the previous quarter

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 70% year-on-year and by 22% since the previous quarter
The ROA has grown by 30% YoY and by 7% from the previous quarter
The ROIC has grown by 8% YoY and by 6% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 67% smaller than its total liabilities
BridgeBio Pharma's quick ratio has plunged by 77% YoY and by 22% from the previous quarter
The current ratio has shrunk by 76% YoY and by 19% QoQ
BBIO's debt is 199% greater than its equity
BBIO's equity is down by 41% year-on-year and by 10% since the previous quarter
BBIO's debt is up by 34% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.